While COVID-19 continues to exacerbate the ongoing opioid crisis in the United States, it has also provided an opportunity for states to adjust how opioid treatment services are delivered around the country using a variety of available mechanisms for change.
States have sought Medicaid Waivers as an emergency tool to quickly amend their existing Medicaid programs to allow for more flexibility, support, and access to services during COVID-19. Though very few states utilized Medicaid Waivers to accommodate substance use disorder treatment specifically, states used Section 1115 Waivers, Section 1135 Waivers and Section 1915(c) modifications to remove prior authorization barriers and increase the use of telehealth during the pandemic more broadly.
This dataset explores three different types of Medicaid Waivers:
This dataset is cross-sectional and displays key features of state Medicaid Waivers addressing COVID-19 across all 50 states and the District of Columbia approved as of July 1, 2021. The data were created with support from JCOIN grant U01DA050442 from the National Institute on Drug Abuse as part of the NIH HEAL Initiative.